| Purpose | Announcement Date | Ex-Date | Record Date | Dividend Amount | Dividend per Share | Remark |
|---|---|---|---|---|---|---|
| Dividend | 30 May 2025 | 22 Sep 2025 | 22 Sep 2025 | 0.4 | 40 | Final |
| Recommended the Final Dividend of ~0.40 Paise (Le., 40%) per equity share of face value of ~1/ each for the financial year 2024-25, subject to approval of the members at the ensuing Annual General Meeting (AGM). The AGM date and book closure / record date for the purpose of the payment of dividend will be informed in due course. Fixation of record date for determining the members eligible to receive dividend for the Financial Year 2024-25 (As Per BSE Announcement Dated on: 09/08/2025) | ||||||
SMS Pharma added that it will submit its formal response to the USFDA within the stipulated timeline, in line with standard regulatory practice.
For the June quarter, SMS Pharma reported a 24.3% year-on-year jump in net profit to ₹20.49 crore, compared with ₹16.48 crore a year earlier.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
